Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

January 04, 2007 10:45 ET

Media Advisory/REMINDER/Ecopia/Caprion: Notice of Conference Call

MONTREAL, QUEBEC--(CCNMatthews - Jan. 4, 2007) - Ecopia Biosciences (TSX:EIA) and Caprion Pharmaceuticals advise of an upcoming conference call and webcast to discuss the combination of both companies and the launch of a $30 million private placement financing announced earlier this morning in a press release. The conference call will take place today, January 04, 2007 at 3:00 p.m. eastern time.

January 04, 2007, conference call and webcast

To listen to the live web cast please call local access: 416-644-3424 or call tool-free 1-800-814-4860 or go to An archived version will be available shortly after the conference on Ecopia's website at Please call five (5) minutes prior to the conference in order to ensure your participation.

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to move our flagship compound ECO-4601 through Phase I clinical trials. ECO-4601 is a novel small molecule that, based on advanced animal models, crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is derived from Ecopia's proprietary drug discovery platform Decipher®. The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at

About Caprion

Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. The Company's clinical-stage programs include Shigamabs®, a product for the treatment of Shigatoxin-producing E. coli bacterial infections, and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. CellCarta®, Caprion's proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious, and identify which patients may benefit most from a particular therapy.

Additional information about Caprion can be obtained from Caprion's website at

Contact Information